Acurx (ACXP) Surges 24% in Volatile Session Amid Strong Bullish Signals — What's Fueling the Move?

Summary
• Acurx’s stock has surged over 24% intraday, reaching as high as $6.91
• The stock is now trading far above its 200-day moving average and 52-week low
• Bollinger Bands suggest extreme volatility with a high of $5.90 and a low of -$0.56
• RSI is pushing into overbought territory at 70.78, signaling potential exhaustion of buying momentum

On a day marked by extreme volatility, Acurx (ACXP) has delivered one of the most striking intraday moves in the pharmaceutical sector, surging over 24% from its morning low. The stock has broken through multiple key resistance levels, suggesting a short-term reversal and bullish continuation pattern. With the RSI entering overbought territory and the MACD histogram positive and rising, traders and investors are watching to see whether this move is the start of a new upward trend or a short-lived breakout.

Bullish Candlestick and Technical Signals Power Acurx’s Intraday Surge
The explosive intraday move in Acurx (ACXP) is driven by a combination of bullish technical patterns and strong momentum indicators. A ‘Bullish Engulfing’ candlestick pattern has formed on the intraday chart, which typically signals a strong reversal from a downtrend. This is further reinforced by the MACD crossing above its signal line and the histogram expanding positively. Additionally, RSI is approaching overbought levels, indicating that buying pressure is strong. These technical signals, together with the stock breaking above the 52-week low and the 200-day moving average, suggest a short-term bullish continuation.

Pharmaceuticals Sector Steadies as Acurx Soars
While Acurx (ACXP) is experiencing a dramatic intraday rally, the broader pharmaceutical sector remains relatively stable. Sector leader Pfizer (PFE) is down by -0.22%, indicating that Acurx’s surge is not part of a broader sector-wide rally. This suggests that the move in ACXP is more likely driven by specific technical factors or a potential catalyst that has not yet been widely reflected in sector news. As such, the pharmaceutical sector is a mixed bag, with ACXP standing out due to its sharp move.

Navigating the Bullish Surge: ETF Positioning and Strategic Technical Reading
• Bold ETF: Vanguard Extended Market ETF (VXF) - Price: $204.7601, Change: -0.698%
• 200-day average: $3.189 (below current price of $6.4761)
• MACD: 0.7393 (rising), Signal Line: 0.3580, Histogram: 0.3813 (expanding bullish)
• RSI: 70.78 (overbought), Bollinger Bands: Upper $5.90 (below current price), Middle $2.67 (far below), Lower -$0.56 (extreme)

Traders navigating this high-volatility session should consider a conservative long position in ACXP, supported by the strong intraday reversal and bullish momentum. While the RSI is in overbought territory, the stock remains well above its key moving averages and the 52-week low, indicating that the move is not overextended. The Vanguard Extended Market ETF (VXF) is currently down, which may limit sector-wide support, but ACXP’s move suggests it is operating independently of sector trends. For those looking to leverage the move without full exposure, a strategic options play could be considered, though the options chain is currently empty, so this must be approached with caution.

Backtest Acurx Stock Performance
The backtest of ACXP's performance after a 24% intraday increase from 2022 to now shows mixed results. While the 3-day win rate is high at 42.86%, the returns over longer periods such as 10 days and 30 days are relatively modest, at 0.52% and 0.55% respectively. This suggests that ACXP may not have been able to capitalize on the intraday gains to sustain long-term growth.

Bullish Momentum Intact — Key Levels to Watch and What to Do Next
Acurx’s (ACXP) dramatic intraday surge reflects strong technical strength and momentum, with the RSI and MACD both confirming a bullish trend. While the stock has moved well above its 200-day average and key support levels, it is now at a critical juncture. Traders should watch for a pullback to the $5.90 level as a key confirmation of whether this rally is sustainable. Meanwhile, sector leader Pfizer (PFE) remains in slight decline, so ACXP’s move should be viewed as independent of broader sector dynamics. For investors with a medium-term outlook, entering a long position now, with a stop just below the $5.0053 intraday low, could be a viable strategy. Aggressive traders should watch for a retest of the $5.90 level and consider initiating a buy on the breakout above that key upper Bollinger Band threshold.